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Introduction {#sec1}
============

Neural stem cells (NSCs), defined as neural precursor cells that can self-renew, give rise to three major cell types: neurons, astrocytes, and oligodendrocytes ([@bib30], [@bib44]). Multipotent NSCs can be isolated and cultured from primary cortical or hippocampal cultures after passage in the presence of mitogenic growth factors ([@bib13]). In cultures of rat embryonic day 14 (E14) cells, cortical NSCs give rise primarily to neurons and dividing precursor cells; astrocytes are generated only when cells are cultured for several days ([@bib14]). The molecular mechanisms by which NSCs undergo differentiation into neurons versus astrocytes are not well understood.

Hippocalcin (HPCA) is a high-affinity calcium-binding protein restricted to the CNS and is most abundant in pyramidal cells of the hippocampus CA1 region ([@bib23]). During brain development HPCA expression increases sharply, concurrent with synapse formation ([@bib46]). HPCA belongs to the family of EF-hand-containing neuronal calcium sensor proteins, which possess a Ca^2+^/myristoyl switch that allows translocation to membranes in response to increased cytosolic Ca^2+^ concentrations. It also regulates mixed-lineage kinase 2, phospholipase D (PLD), and neuronal apoptosis inhibitory protein ([@bib3], [@bib21], [@bib25], [@bib31], [@bib36], [@bib37]). We have reported that HPCA is a major regulatory protein in the Ca^2+^-mediated PLD signaling pathway ([@bib38]) and that it induces expression of Neuro-D, leading to neurite outgrowth in H19-7 cells during differentiation ([@bib39]). It is possible that HPCA regulates neurogenesis through these molecules; however, molecular mechanisms by which HPCA affects neuronal/astrocyte cell-fate decision have not been studied.

PLD is a ubiquitous enzyme that catalyzes the hydrolysis of phosphatidylcholine (PC) to phosphatidic acid and choline ([@bib10]). Phosphatidic acid (PA) itself acts as a cellular messenger or can be transformed by PA phosphohydrolase into diacylglycerol, which is essential for activation of protein kinase C (PKC) ([@bib26], [@bib60]). PKCα regulates Ca^2+^-dependent differentiation in several cell lines and primary cells ([@bib24], [@bib43]) and plays an essential role in synaptic plasticity by raising intracellular Ca^2+^ levels in neurons ([@bib24]). Activation and phosphorylation of PLD1 are regulated by PKCα in phorbol myristate acetate-treated COS-7 cells, and a similar interrelationship between PLD and PKC isoforms is seen in a variety of cell types ([@bib20]). Recent studies have reported that PLD plays a key role in neuronal differentiation of cells such as PC12 cells ([@bib1]) and cerebellar granule neurons ([@bib53]). We have also reported that it has a critical role in the neuronal differentiation of rat NSCs ([@bib57]) and H19-7 cells ([@bib59]). However, the relevance of PLD1 signaling in neuronal differentiation remains unclear.

The signal transducer and activator of transcription (STAT) family participates in the regulation of genes involved in the acute phase of inflammatory response, cell growth, and cell differentiation ([@bib42]). Among them, STAT3 is an important transcription factor for the regulation of glial fibrillary acidic protein (GFAP) expression, and the DNA binding of STAT3 was shown to be affected by phosphorylation of the Ser727 or/and Tyr705 site ([@bib56]). STAT3 binds to different domains of CBP/p300, and the STAT/p300/Smad complex, acting at the STAT-binding element in the astrocyte-specific GFAP promoter, is particularly effective at inducing astrocyte differentiation in NSCs ([@bib32]). Moreover, STAT3 signaling is upregulated in certain neurodegenerative diseases ([@bib49]), and in vitro suppression of *Stat3* or its conditional deletion in vivo promoted neurogenesis and inhibited astrogliogenesis ([@bib5], [@bib15]). Thus, STAT3 is considered an attractive target for promoting neurogenesis. In our previous study, STAT3 activation is associated with PLD2 through the S6K1-ERK pathway in lipopolysaccharide (LPS)-induced inflammation mechanism ([@bib42]), but the relationship between PLD1 signaling and STAT3 function is not yet defined. Thus, the present study showed that PLD1 is required for HPCA-mediated STAT3 activation of neuronal differentiation. In addition, a number of protein tyrosine phosphatases negatively regulate STAT3 signaling through direct dephosphorylation of p-STAT3(Y705); these include members of the SH2-domain-containing tyrosine phosphatase family (SHP-1 and SHP-2) and protein tyrosine phosphatase 1B (PTP-1B) ([@bib16]). More specifically, SHP-1 regulates STAT3(Y705) phosphorylation in Huh-7 HCC, PLC5, and HepG2 cells ([@bib7]). Thus, activity of SHP-1 may be critical for regulating STAT3 phosphorylation in neuronal differentiation.

In this study, we aimed to clarify the role of HPCA in the neuronal differentiation of NSCs. Our findings indicate that HPCA is essential for neurogenesis of NSCs, and that it promotes neuronal differentiation and inhibits astrocytic differentiation.

Results {#sec2}
=======

HPCA Is Required for Neuronal Differentiation in NSCs {#sec2.1}
-----------------------------------------------------

Many studies of the neurogenic-to-gliogenic switch have focused on the developing neocortex ([@bib44], [@bib48]). We show here that HPCA is expressed in the cerebral neocortex of the E14 rat brain ([Figure 1](#fig1){ref-type="fig"}A) and examine its possible role in neuronal differentiation using cortical NSCs. During growth of these cells, basic fibroblast growth factor (bFGF) was present to prevent differentiation and promote proliferation. To investigate the role of HPCA in neuronal differentiation, we removed bFGF for 24 hr. As shown in [Figure 1](#fig1){ref-type="fig"}B, mRNA expression of *Hpca* and the protein level of HPCA were markedly increased under differentiation conditions. Nerve growth factors such as NT-3, NT4/5, and BDNF, together with the basic helix-loop-helix transcription factors Neuro-D and neurogenin-1 (NGN1), are closely associated with neuronal differentiation and can be used as markers of this process ([@bib27], [@bib50]). Therefore, we generated NSCs that overexpressed *Hpca* and monitored the levels of neuronal differentiation markers. As shown in [Figures 1](#fig1){ref-type="fig"}C and 1D, the expression levels of *Nt3*, *Nt4*/*5*, *Bdnf*, *Neuro-D*, and *Ngn1* were significantly enhanced by *Hpca* overexpression compared with the vector control in the absence of bFGF. NSCs are considered as the primary progenitor cells for neuronal and glial cell lineages during development ([@bib45]). We examined the effects of HPCA on the expression of neuronal and glial markers during neuronal differentiation. In the absence of bFGF, *Hpca* overexpression resulted in markedly enhanced expression of neuron-specific class III β-tubulin (TUJ1, a neuronal marker), while GFAP expression was significantly decreased by *Hpca* when compared with the vector control ([Figure 1](#fig1){ref-type="fig"}E). These data suggest that HPCA promotes neuronal differentiation and suppresses astrocyte differentiation in NSCs.

We reported previously that HPCA leads to neurite outgrowth of H19-7 cells ([@bib39]). To confirm its role in neurite outgrowth in NSCs, we exposed cells to EGFP-tagged *Hpca* for 2 days. After 3 days of differentiation, neurite outgrowth was measured under a fluorescence microscope (EGFP-transfected cells fluoresce green, TUJ1-stained cells fluoresce red, and cells transfected with both EGFP and TUJ1 fluoresce yellow) ([Figure 1](#fig1){ref-type="fig"}F). Neurons and astrocytes were quantified by normalizing the total number of TUJ1- and GFAP-positive cells to the total number of DAPI-labeled cell nuclei. When *Hpca* was introduced, neurite outgrowth (97.1 ± 8.3 μm versus 135.2 ± 14.1 μm, p \< 0.05, [Figure 1](#fig1){ref-type="fig"}G) and the number of TUJ1-positive cells (43.2% ± 5.5% versus 64.1% ± 9.9%, p \< 0.05, [Figure 1](#fig1){ref-type="fig"}H) were enhanced, indicating that HPCA plays an important role in NSC neurite outgrowth.

PKCα Is Involved in HPCA-Mediated Expression of TUJ1 in NSCs {#sec2.2}
------------------------------------------------------------

HPCA is a Ca^2+^-binding protein in the neuronal Ca^2+^ sensor family of proteins, which possess a Ca^2+^/myristoyl switch that allows translocation to membranes in response to increased cytosolic Ca^2+^ levels ([@bib40]). Therefore, we analyzed intracellular Ca^2+^ mobilization in fluo-3-loaded NSCs. When the cells were induced to differentiate by removal of bFGF, intracellular Ca^2+^ levels increased ([Figures 2](#fig2){ref-type="fig"}A and 2B). We also observed translocation of HPCA from the cytosol to the membrane after bFGF removal ([Figure 2](#fig2){ref-type="fig"}C), suggesting that binding of Ca^2+^ to HPCA induces a conformational change that promotes membrane association.

To confirm that increased Ca^2+^ levels represent intracellular Ca^2+^, we pretreated cells with EGTA, an extracellular Ca^2+^chelator, before inducing differentiation. The EGTA had no effect on neurite outgrowth ([Figure 2](#fig2){ref-type="fig"}D) or TUJ1-positive cells ([Figure 2](#fig2){ref-type="fig"}E), indicating that HPCA is responsible for the locational changes induced by the increase of intracellular Ca^2+^. HPCA has three putative Ca^2+^-binding domains of the EF-hand structure and a possible NH~2~-terminal myristoylation site, which is referred to as a "calcium/myristoyl switch" and considered to be primarily a mechanism by which the protein can be translocated from the cytosol to the membrane. Both structural features are known to regulate the intracellular Ca^2+^-dependent activation of HPCA. To determine whether Ca^2+^ binding is required for the expressions of HPCA-mediated nerve growth factors, we constructed *Hip*~*1-72*~ (N-terminal domain without all three functional EF hands \[EF2--4\]) and *Hip*~*65-193*~ (calcium-binding domain without myristoylation motif) deletion mutants using the pMSCV-IRES-EGFP-*Hpca*-*Myc* ([Figures 2](#fig2){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}). As shown in [Figures 2](#fig2){ref-type="fig"}G and 2H, *Hpca*-induced expression levels of *Nt3*, *Nt4*/*5*, *Bdnf*, *Neuro-D*, *and Ngn1* were significantly decreased by the *Hip*~*1--72*~ (N-terminal domain) or *Hip*~*65--193*~ (calcium-binding domain). This result indicated that HPCA-mediated expressions of nerve growth factors are dependent on Ca^2+^ binding as well as the myristoylation of HPCA during neuronal differentiation. To further investigate whether HPCA-mediated expressions of nerve growth factors depend on myristoylation, we made constructs with the second glycine residue, essential for myristoylation, mutated to an alanine (G2A) in HPCA protein. As shown in [Figures 2](#fig2){ref-type="fig"}I and 2J, G2A decreased *Hpca*-induced expression levels of *Nt3*, *Nt45*, *Bdnf*, *Neuro-D*, *and Ngn1* in the absence of bFGF. This result suggests that myristoylation is essential for expression of nerve growth factors during neuronal differentiation of NSCs.

Interestingly, increased Ca^2+^ levels regulate PKCα activation and translocation to the membrane from the cytosol in various processes ([@bib2], [@bib6]). Therefore, we analyzed translocation of PKCα after depleting bFGF. Translocation of PKCα from the cytosol to the membrane occurred when neuronal differentiation was induced ([Figure 2](#fig2){ref-type="fig"}K). In addition, the translocation was further enhanced by overexpression of *Hpca* ([Figure 2](#fig2){ref-type="fig"}K). Based on our results, we hypothesized that Ca^2+^-bound HPCA binds PKCα after removal of bFGF. To test this hypothesis, we used immunoprecipitation to determine whether HPCA directly binds to PKCα during neuronal differentiation. As shown in [Figure 2](#fig2){ref-type="fig"}L, HPCA binds to PKCα after removal of bFGF, indicating that Ca^2+^-binding HPCA directly binds to PKCα. Next, to investigate whether HPCA affects PKCα activation, we knocked down *Hpca* in NSCs using *Hpca* siRNA. This resulted in decreased phosphorylation of PKCα ([Figure 2](#fig2){ref-type="fig"}M). To further investigate whether PKCα regulates HPCA-mediated neuronal differentiation, we pretreated NSCs with the PKCα inhibitor RO320432 for 30 min before inducing differentiation by removing bFGF. Inhibition of PKCα markedly reduced *Hpca*-induced expression of TUJ1, whereas GFAP increased ([Figure 2](#fig2){ref-type="fig"}N), demonstrating that PKCα is implicated in HPCA-mediated neuronal differentiation.

We next asked which signaling pathway was responsible for PKCα activation during neuronal differentiation in NSCs. PDK1 plays a central role in many signal transduction pathways by phosphorylating a site in the activation loop of PKC isoforms and initiating their maturation ([@bib8], [@bib54]). To determine whether PDK1 could enhance phosphorylation of PKCα, we pretreated cells with the PDK1 inhibitors GSK2334470 or BAG956 for 30 min. Inhibition of PDK1 abolished phosphorylation of PKCα, indicating that PDK1 regulates PKCα activation during neuronal differentiation ([Figure 3](#fig3){ref-type="fig"}A). In addition, GSK2334470 not only decreased transcripts of *Nt3*, *Nt4*/*5*, *Bdnf*, and *Neuro-D* ([Figures 3](#fig3){ref-type="fig"}B and 3C) but also significantly reduced neurite length (125 ± 14.3 μm versus 45.3 ± 3.3 μm, p \< 0.05, [Figures 3](#fig3){ref-type="fig"}D and 3E) and the number of TUJ1-positive cells (47.2% ± 10% versus 18.5% ± 4%, p \< 0.05, [Figure 3](#fig3){ref-type="fig"}F) when compared with removal of bFGF. Taken together, these results demonstrate that PDK1 signals upstream of PKCα trigger neurite outgrowth, leading to expression of neuronal factors in NSCs. However, the mechanism by which PDK1 affects HPCA-mediated PKCα activation is still unknown. We hypothesized that HPCA brings PKCα to PDK1, after which PDK1 activates PKCα. To test this hypothesis, we used co-immunoprecipitation to determine whether HPCA contributes to binding between PDK1 and PKCα. HPCA stimulated this binding and promoted PKCα activation ([Figure 3](#fig3){ref-type="fig"}G), supporting the idea that HPCA induces the formation of a PDK1-PKCα complex that promotes PKCα phosphorylation during neuronal differentiation.

Effect of PLD1 Activation on HPCA-Mediated Neuronal Differentiation {#sec2.3}
-------------------------------------------------------------------

We previously reported that PLD1 is involved in various neuronal signaling pathways and is an important regulator of neuron function ([@bib58], [@bib59]). We also showed that HPCA increased the activity and expression of PLD in various cell types ([@bib17], [@bib38]). In the present study, we found that PLD1 co-localized with HPCA in the cerebral neocortex of the E14 rat brain ([Figure 4](#fig4){ref-type="fig"}A) and therefore hypothesized that PLD1 was implicated in the HPCA-mediated neuronal differentiation of NSCs. Since PLD1 is regulated by PKCα in NSCs ([@bib43]), we examined whether HPCA-activated PKCα affects PLD activation during neuronal differentiation. We found that in the absence of bFGF, *Hpca*-induced PLD activation was decreased by the PKCα inhibitor RO320432 ([Figure 4](#fig4){ref-type="fig"}B). To further elucidate the role of HPCA in PLD activation, we transfected cells with *Hpca* small interfering RNA (siRNA). Knockdown of *Hpca* markedly inhibited PLD1 phosphorylation, which is related to PLD1 activation ([Figure 4](#fig4){ref-type="fig"}C). To determine the role of HPCA-mediated PLD1 activation in neuronal differentiation, we knocked down *Hpca* or *Pld1* using siRNA and found that the number of TUJ1-positive cells significantly decreased due to knockdown of *Hpca* or *Pld1*, whereas the number of GFAP-positive cells increased ([Figure 4](#fig4){ref-type="fig"}D). These results suggest that HPCA-dependent PLD1 activation is required for neuronal differentiation of NSCs.

To test whether HPCA and PLD1 promote spine formation, which implies synapse formation during neuronal differentiation, we examined dendritic spine formation in cells transfected with siRNA for *Hpca* or *Pld1*. Dendritic spines were significantly decreased by knockdown of *Hpca* or *Pld1* ([Figures 4](#fig4){ref-type="fig"}E and 4F). Taken together, these results indicate that PLD1 plays an important role in HPCA-mediated neuronal differentiation of NSCs.

Inhibition of STAT3(Y705) Activation Increases Neuronal Differentiation in NSCs {#sec2.4}
-------------------------------------------------------------------------------

The determination of neuronal/glial fate during CNS development involves complex interactions between intrinsic signals that act through many transcription factors ([@bib9]). STAT3 inhibition enhances differentiation of human NSCs to motor neurons and reduces astrocytosis, and similarly induces neurogenesis and inhibits gliogenesis ([@bib5], [@bib33]), supporting our hypothesis that STAT3 activation inhibits neuronal differentiation and promotes astrocytic differentiation. We therefore examined whether HPCA affects STAT3 activation. *Hpca* was transfected into NSCs for 2 days and differentiation was induced for 1 day. As shown in [Figure 5](#fig5){ref-type="fig"}A, *Hpca* increased the dephosphorylation of p-STAT3(Y705) compared with the vector control, even in the absence of bFGF, but did not affect p-STAT3(S727). Moreover, bFGF removal-induced p-STAT3(Y705) dephosphorylation and TUJ1 expression were abolished by *Hpca* siRNA while GFAP expression was enhanced ([Figures 5](#fig5){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}), suggesting that *Hpca*-induced dephosphorylation of p-STAT3(Y705) is crucial for the promotion of neuronal differentiation. To further investigate whether dephosphorylation of p-STAT3(Y705) is essential for the neuronal differentiation of NSCs, we prepared *Stat3*YF mutant (point mutation of tyrosine 705 to phenylalanine 705). When *Stat3*WT (wild-type) and *Stat3*YF were transfected into HEK293 cells, respectively, STAT3 was successfully overexpressed ([Figure S3](#mmc1){ref-type="supplementary-material"}). We validated *Stat3*YF mutant by showing the disappearance of LPS-induced tyrosine phosphorylation of STAT3(Y705) ([Figure S3](#mmc1){ref-type="supplementary-material"}). Next, we determined the effects of *Stat3*YF on the expression of neuronal and glial markers during differentiation of NSCs. *Stat3*YF resulted in markedly enhanced TUJ1 expression while GFAP expression was significantly decreased by removal of bFGF when compared with the *Stat3*WT ([Figure 5](#fig5){ref-type="fig"}D). In addition, *Stat3*YF significantly increased the number of TUJ1-positive cells (63.4% ± 9% versus 19.2% ± 2%, p \< 0.05, [Figures 5](#fig5){ref-type="fig"}E and 5F) and neurite length (147.2 ± 20.3 μm versus 75.8 ± 6.9 μm, p \< 0.05, [Figures 5](#fig5){ref-type="fig"}E and 5G), whereas it decreased the number of GFAP-positive cells (18.8% ± 1.2% versus 52.5% ± 10.1%, [Figures 5](#fig5){ref-type="fig"}E and 5F) when compared with *Stat3*WT with bFGF removal. Consistent with these results, *Stat3*YF markedly enhanced expression levels of *Nt3*, *Nt4*/*5*, *Bdnf*, *Neuro-D*, and *Ngn1* by withdrawal of bFGF when compared with the *Stat3*WT ([Figure S4](#mmc1){ref-type="supplementary-material"}). These results indicate that inhibition of STAT3(Y705) activity promotes neuronal differentiation accompanied by suppressed astrocytic differentiation.

Next, we asked whether p-STAT3(Y705) played a role in HPCA-mediated neuronal differentiation in NSCs. *Hpca*-induced TUJ1 expression was increased by *Stat3*YF, while GFAP expression was significantly decreased when compared with *Stat3*WT with bFGF removal ([Figure 5](#fig5){ref-type="fig"}H). In addition, *Stat3*YF increased *Hpca*-induced TUJ1-positive cells (55.4% ± 9% versus 18.3% ± 1.2%, p \< 0.05, [Figures 5](#fig5){ref-type="fig"}I and 5J) and neurite length (178.6 ± 11.3 μm versus 101.2 ± 18 μm, p \< 0.05, [Figures 5](#fig5){ref-type="fig"}I and 5K) compared with *Stat3*WT/*Hpca* with bFGF removal. By contrast, *Stat3*YF decreased GFAP-positive cells (14.9% ± 2% versus 32.2% ± 2%, p \< 0.05, [Figures 5](#fig5){ref-type="fig"}I and 5J) compared with *Stat3*WT with bFGF removal in *Hpca*-transduced cells. These results suggest that p-STAT3(Y705) inhibits *Hpca*-induced neuronal differentiation, leading to astrocyte differentiation in NSCs.

SHP-1 Is Essential for Neuronal Differentiation of NSCs {#sec2.5}
-------------------------------------------------------

Protein tyrosine phosphatases, such as SHP-1, SHP-2, and PTP-1B, negatively regulate STAT3 signaling through direct dephosphorylation of p-STAT3(Y705) ([@bib41], [@bib55]). Thus, the activity of protein tyrosine phosphatases may be critical for the regulation of STAT3 phosphorylation in NSCs. SHP-1 is a negative regulator of p-STAT3(Y705) ([@bib7]). Therefore, we examined the participation of SHP-1 in dephosphorylation of p-STAT3(Y705) during neuronal differentiation in NSCs. First, we showed that PTPI(1), an inhibitor of SHP-1, increased STAT3(Y705) phosphorylation and GFAP expression, while TUJ1 expression decreased ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}) in *Hpca*-induced NSCs during differentiation. Translocation of STAT3 to the nucleus from the cytosol is known to reflect STAT3 activation ([@bib18]). Therefore, we determined whether SHP-1 affected the translocation of STAT3 to the nucleus during neuronal differentiation. We found that PTPI(1) indeed enhanced its translocation to the nucleus ([Figure 6](#fig6){ref-type="fig"}B), indicating that SHP-1 is sufficient to reduce STAT3 activation, most likely by lowering nuclear STAT3. Furthermore, the number of TUJ1-positive cells was decreased by PTPI(1), whereas the number of GFAP-positive cells was increased ([Figures 6](#fig6){ref-type="fig"}C and 6D), indicating that HPCA-mediated SHP-1 activation is critical for neuronal differentiation by promoting neurogenesis and inhibiting gliogenesis. In addition, the role of SHP-1 in STAT3 activation was confirmed in a *Shp-1* knockdown study. *Shp-1* siRNA abolished dephosphorylation of p-STAT3(Y705), suggesting a crucial role of SHP-1 in STAT3(Y705) phosphorylation ([Figure 6](#fig6){ref-type="fig"}E). We also found that SHP-1 bound to p-STAT3(Y705) during differentiation, and that this binding was promoted by *Hpca* ([Figure 6](#fig6){ref-type="fig"}F). This suggests that HPCA promotes the formation of an SHP-1/p-STAT3(Y705) complex, leading to dephosphorylation of p-STAT3(Y705) during neuronal differentiation.

Activation of SHP-1 by acidic phospholipids such as PA may help to regulate SHP-1 activity ([@bib12]). PA is the functional enzymatic product of PLD activity ([@bib11]). As SHP-1 activity can be influenced by tyrosine phosphorylation, we determined whether tyrosine phosphorylation of SHP-1 is regulated by PA. Exogenously added PA induced phosphorylation of SHP-1 and dephosphorylation of STAT3 in a dose-dependent manner ([Figure 7](#fig7){ref-type="fig"}A). We next determined whether PLD1, the major source of PA, affects SHP-1 phosphorylation. *Pld1* knockdown inhibited SHP-1 phosphorylation ([Figure 7](#fig7){ref-type="fig"}B), and *Pld1* siRNA affected dephosphorylation of STAT3 ([Figure S6](#mmc1){ref-type="supplementary-material"}). These results suggest that SHP-1/STAT3 activation is regulated by PLD1 activation. We further showed that phosphorylation of SHP-1 was decreased by *Hpca* knockdown ([Figure 7](#fig7){ref-type="fig"}C). In addition, silencing *Hpca* or *Pld1* with siRNA decreased SHP-1 phosphatase activity ([Figure 7](#fig7){ref-type="fig"}D), as expected.

To confirm the role of SHP-1 in neuronal differentiation, we knocked down *Shp-1*, which decreased TUJ1-positive cells, increased GFAP-positive cells ([Figures 7](#fig7){ref-type="fig"}E and 7F), and significantly reduced neurite length compared with control siRNA (24.5 ± 6 μm versus 103.2 ± 8 μm, p \< 0.05) ([Figure 7](#fig7){ref-type="fig"}G). Furthermore, the number of dendritic spines was greatly decreased by *Shp-1* siRNA ([Figure 7](#fig7){ref-type="fig"}H). These results confirm that SHP-1 is an important regulator of neurogenesis.

Discussion {#sec3}
==========

In the present study, we have shown that HPCA is an important regulator of the neuronal differentiation of NSCs and that it promotes neurogenesis and inhibits gliogenesis. HPCA expression markedly increased during differentiation of NSCs isolated from the cerebral cortex in the E14 rat brain. In addition, neurite outgrowth was enhanced by overexpression of *Hpca*, indicating that HPCA could be an important player in neuronal differentiation in the brain. Studies of the signal transduction pathways that lead to neuronal differentiation have been impeded by limitations in the genetic manipulation and biochemical analysis of primary neuronal cells, including NSCs. Nevertheless, we have identified a mechanism of HPCA action that promotes neurogenesis. HPCA recruits PKCα to PDK1, which facilitates the PKCα-regulated kinase cascade; PKCα-dependent PLD1 activation is required for HPCA-mediated neurite outgrowth. PA, a functional product of PLD1, affects tyrosine phosphatase SHP-1 activation during neuronal differentiation, and SHP-1 blocks STAT3(Y705) activation, thereby inhibiting gliogenesis in NSCs ([Figure 7](#fig7){ref-type="fig"}I). Thus, this signaling pathway provides insight into HPCA-mediated neuronal function in rat NSCs and its potential contribution to cell-fate signaling.

HPCA Promotes Neurogenesis by Inhibiting Gliogenesis {#sec3.1}
----------------------------------------------------

The specification of cell fate involves the commutative activation of genes related to a particular cell fate and the inhibition of genes related to alternative fates. Cell-fate-specifying transcription factors can both positively and negatively regulate alternative fates ([@bib47], [@bib52]), and a recent study reported that NGN1 has dual functions in activating neuronal differentiation genes and suppressing glial differentiation genes ([@bib51]). Similarly, our study suggests that HPCA positively regulates neurogenesis and negatively regulates gliogenesis in NSCs. This is supported by our findings that: (1) knockdown of *Hpca* strongly decreased neurite outgrowth and dendritic spinogenesis, whereas it increased expression of the astrocyte marker GFAP and GFAP-positive cells; and (2) overexpression of *Hpca* significantly stimulated neurite outgrowth and expression of the neuron marker TUJ1, even in the presence of bFGF. These results are consistent with the concept that a specific gene product such as *Ngn-1* inhibits glial differentiation ([@bib34]).

The Role of HPCA in PKCα/PLD1 Activation during Neuronal Differentiation {#sec3.2}
------------------------------------------------------------------------

HPCA has a Ca^2+^/myristoyl switch, allowing membrane translocation from the cytosol in response to increased free Ca^2+^ concentrations ([@bib37]). In neurons, HPCA is located in the cytoplasm and plasma membrane of cell bodies, dendrites, and axons ([@bib4]). HPCA exerts a neuroprotective action by blocking the formation of Ca^2+^-induced cell death stimuli ([@bib29]), and infusion of a mutant *Hpca* lacking Ca^2+^-binding sites prevents long-term depression in hippocampal neurons ([@bib19]). Since HPCA has a crucial role in Ca^2+^-mediated neuronal activity in the brain, we investigated its potential role in Ca^2+^-dependent signaling pathways in NSCs. When cells were induced to differentiate by removal of bFGF, Ca^2+^ levels increased and HPCA translocated to the membrane. Furthermore, HPCA assisted the formation of a PDK1-PKCα complex, which induces PKCα phosphorylation. As summarized in [Figure 7](#fig7){ref-type="fig"}I, it is not known whether HPCA has direct or indirect effects on PDK1 activation or binds to PDK1. Moreover, the molecular mechanism responsible for the phosphorylation of PDK1 by differentiation stimulus has not yet been defined. Thus, further studies are needed to clarify the relationship between HPCA and PDK1 signaling during neuronal differentiation in NSCs; this could be important for a complete understanding of HPCA-mediated signaling cascade in neurogenesis of NSCs. Our previous studies showed that HPCA played a role in Ca^2+^-dependent PLD activation ([@bib17]), and PLD1 promotes neurite outgrowth in H19-7 cells ([@bib59]). As expected, PLD1 is involved in HPCA-mediated neurogenesis and its activation is regulated by HPCA. Taken together, our results suggest that HPCA is required for optimal formation of a complex between PDK1 and PKCα, resulting in PLD1 activation during neuronal differentiation.

Blocking of STAT3(Y705) Activation by HPCA Increases Neuronal Differentiation and Decreases Astrocytic Differentiation of NSCs {#sec3.3}
------------------------------------------------------------------------------------------------------------------------------

STAT3 plays essential roles in determining the fate of NSCs ([@bib5]). In the present study, NSC differentiation induced by removal of bFGF resulted in a dramatic reduction in the phosphorylation of STAT3(Y705). Interestingly, HPCA\'s inhibition of STAT3(Y705) phosphorylation induced neurogenesis and decreased gliogenesis. Furthermore, *Stat3*YF mutant significantly promotes *Hpca*-induced TUJ1 expression and TUJ1-positive cells, while it failed to stimulate GFAP expression and GFAP-positive cells. Our results are consistent with earlier reports in which suppression or conditional deletion of *Stat3* promotes neuronal differentiation and inhibits glial differentiation ([@bib15], [@bib33]). The activities of intracellular transcription factors are controlled by the competing activities of kinases and phosphatases ([@bib28]). We found that SHP-1 led to loss of STAT3(Y705) activation. Interestingly, SHP-1 binds to phosphorylated STAT3(Y705) under differentiation conditions and this process was promoted by HPCA. Thus, we conclude that HPCA-mediated SHP-1 activity most likely inhibits STAT3 activity by blocking its import to the nucleus and, presumably, by decreasing the nuclear accumulation of phosphorylated STAT3(Y705), resulting in increased neurogenesis.

In summary, HPCA appears to have two distinct roles: promoting neurogenesis and inhibiting gliogenesis. We propose that it has an important role in enhancing the generation of neurons from NSCs. Neurogenesis is tightly controlled because of its critical importance in proper physiological function, and multiple signals control the growth and directionality of the relevant cell-fate decision. However, the mechanism by which HPCA affects Ca^2+^-dependent signaling during neurogenesis remains to be determined, and a more detailed characterization of the mechanisms is currently under way. HPCA may be implicated in memory formation, neuronal excitability, and activity-dependent plasticity ([@bib23]). *Hpca* knockout (*Hpca*^−/−^) mice have a defect in CREB activation that is associated with impaired spatial and associative memory ([@bib22]) as well as an impaired RAS-regulated kinase cascade in response to RAF activation ([@bib35]). It is possible that HPCA plays an important role in long-lasting neural plasticity and promotes spatial and associative memory. Nevertheless, despite recent progress, much remains unknown regarding the contribution of HPCA-mediated signaling mechanisms to brain injury and recovery. Further studies are required to address its possible use as a marker of neurodegenerative disorders and in promoting neuronal regeneration in vivo.

Experimental Procedures {#sec4}
=======================

Preparation of Animal Tissue {#sec4.1}
----------------------------

All experimental animal procedures (Sprague-Dawley rats) were approved by the Institutional Animal Care and Use Committee (IACUC) at Hanyang College of Medicine under approval number 2015-0009. Experiments were performed in accordance with the NIH guidelines.

Primary Culture of Neural Precursor Cells {#sec4.2}
-----------------------------------------

Embryonic brain cortices from E14 rat embryos were mechanically triturated in Ca^2+^/Mg^2+^-free Hank\'s balanced salt solution (HBSS; Gibco), seeded at 2 × 10^5^ cells in 10-cm culture dishes (Corning Life Sciences), which were precoated with 15 μg/mL poly-L-ornithine (Sigma) and 1 μg/mL fibronectin (Invitrogen) and then cultured for 5--6 days in serum-free N2 medium supplemented with 20 ng/mL bFGF (R&D Systems). Cell clusters generated by precursor cell proliferation were dissociated in HBSS and plated at 2 × 10^4^ cells per well on coated 24-well plates, 2 × 10^5^ cells per well on coated 6-well plates, and 8 × 10^5^ cells per dish on coated 6-cm culture dishes. The plated cells were allowed to proliferate further in N2 + bFGF up to 70%--80% cell confluence before induction of differentiation. All experiments were carried out using the passage 1 (P1) neural precursor cells.

Other Procedures {#sec4.3}
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![Effect of HPCA Expression during Neuronal Differentiation of NSCs\
(A) HPCA immunostaining of coronal sections of E14 rat brain cortex. The boxed area is magnified. Scale bar, 20 μm.\
(B) Neuronal differentiation was induced by removal of bFGF for 1 day, and *Hpca* mRNA expression was analyzed by RT-PCR. Twenty micrograms of protein was analyzed by western blotting with anti-HPCA and anti-β-ACTIN.\
(C and D) NSCs were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and allowed to differentiate for 24 hr. mRNA levels of neuronal factors were analyzed by RT-PCR (C) and real-time RT-PCR (D). ^∗^p \< 0.05 compared with the −bFGF/vector control (mean ± SD; n = 3).\
(E) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and induced to differentiate for 24 hr. Levels of TUJ1, GFAP, MYC, and β-ACTIN were determined by western blot. ^∗^p \< 0.05 compared with the −bFGF/vector control (mean ± SD; n = 3).\
(F) Cells were transduced with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* and induced to differentiate by withdrawal of bFGF. After 3 days, GFP-positive cells were examined by fluorescence microscopy and stained with anti-EGFP (green) and anti-TUJ1 (red). Scale bar, 20 μm.\
(G and H) Neurite lengths were measured and the proportions of TUJ1-positive cells and total cells were determined in randomly selected areas from at least three slides of each condition. ^∗^p \< 0.05 compared with the −bFGF/vector control (mean ± SD; n = 3).](gr1){#fig1}

![Increased Intracellular Ca^2+^ Affects HPCA-PKCα Activation during Neuronal Differentiation of NSCs\
(A and B) NSCs were used for fluo-3/AM Ca^2+^ imaging 1 day after plating on poly-L-lysine-coated glass coverslips (see [Experimental Procedures](#sec4){ref-type="sec"}). We collected images every 1 s at 470 nm excitation/514 nm emission using Metafluor software. The threshold of increased intracellular Ca^2+^ was defined as a 20% increase from the basal level.\
(C) Cells were depleted with bFGF for 5 min, fixed, and immunostained with anti-HPCA (red). The boxed area is magnified. Scale bar, 5 μm.\
(D and E) Cells were pretreated with 500 μM EGTA for 1 day and incubated for 3 days after removal of bFGF. After immunostaining with anti-TUJ1, TUJ1-positive cells were counted under fluorescence microscopy. The proportion of TUJ1-positive cells and total cells was determined in random areas from at least three slides of each condition. Data are shown as mean ± SD (n = 3). N.S, not significant (p *=* 0.245). Scale bar, 20 μm.\
(F) Schematic of *Hpca* (wild-type) and its deletion mutants.\
(G and H) NSCs were transfected with pMSCV-IRES-EGFP, pMSCV-IRES-EGFP-*Hpca*-*Myc*, pMSCV-IRES-EGFP-*Hip*~*1-72*~-*Myc*, or pMSCV-IRES-EGFP-*Hip*~*65-193*~-*Myc* for 48 hr and induced to differentiate for 24 hr. mRNA levels of neuronal factors were analyzed by RT-PCR (G) and real-time RT-PCR (H). ^∗^p \< 0.05 compared with −bFGF/*Hpca* (mean ± SD; n = 3).\
(I and J) G2 is a key residue for myristoylation of HPCA. NSCs were transfected with pMSCV-IRES-EGFP, pMSCV-IRES-EGFP-*Hpca*-*Myc*, or pMSCV-IRES-EGFP-*Hpca* G2A-*Myc* for 48 hr and induced to differentiate for 24 hr. mRNA levels of neuronal factors were analyzed by RT-PCR (I) and real-time RT-PCR (J). ^∗^p \< 0.05 compared with −bFGF/*Hpca* (mean ± SD; n = 3).\
(K) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and induced to differentiate by withdrawal of bFGF for 24 hr. Cells were then lysed and centrifuged at 100,000 × *g* to separate cytosolic and membrane fractions. Samples of protein (30 μg) from each fraction were analyzed by western blotting with anti-PKCα, anti-MYC, anti-integrin α2, and anti-GAPDH. Data are shown as mean ± SD (n = 3).\
(L) Cells were transfected with p-MSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr, and induced differentiate for 24 hr. Immunoprecipitates (IP) from the cell lysates with anti-MYC were analyzed by western blotting with anti-PKCα and anti-MYC.\
(M) Cells were transiently transfected with control siRNA or *Hpca* siRNA for 48 hr, then incubated for 1 day after removal of bFGF. Proteins were analyzed by western blotting with anti-p-PKCα, anti-PKCα, anti-HPCA, and anti-GAPDH. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(N) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and then treated with 10 μM RO320432 for 30 min before differentiation for 1 day. Cells were lysed and analyzed by western blotting with anti-TUJ1, anti-GFAP, anti-MYC, and anti-GAPDH. ^∗^p \< 0.05 compared with −bFGF/*Hpca* (mean ± SD; n = 3).](gr2){#fig2}

![PDK1 Is Involved in HPCA-Mediated PKCα Activation and Neuronal Differentiation of NSCs\
(A) NSCs were pretreated with 5 μM GSK2334470 or 10 μM BAG956 for 30 min before differentiation for 1 day. Cells were lysed and analyzed by western blotting with anti-p-PKCα, anti-PKCα, anti-p-PDK1, anti-PDK1, and anti-GAPDH.\
(B and C) Cells were pretreated with 5 μM GSK 2334470 and allowed to differentiate for 1 day. mRNA levels of neuronal factors were analyzed by RT-PCR (B) and real-time RT-PCR (C). ^∗^p \< 0.05 compared with the −bFGF control (mean ± SD; n = 3).\
(D) Cells were pretreated with 5 μM GSK2334470 and induced to differentiate by withdrawal of bFGF. After differentiation for 3 days, fixed cells were immunostained with anti-TUJ1 (green) and anti-GFAP (red). Scale bar, 20 μm.\
(E and F) Neurite lengths were measured and the numbers of TUJ1-positive cells and total cells were determined in randomly selected areas from at least three slides of each condition. ^∗^p \< 0.05 compared with the −bFGF control (mean ± SD; n = 3).\
(G) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr, and induced to differentiate for 24 hr. Immunoprecipitates from the cell lysates with anti-PDK1 were analyzed by western blotting with anti-p-PKCα, anti-PKCα, anti-PDK1, and anti-MYC.](gr3){#fig3}

![PLD1 Is Required for *Hpca*-Induced Neuronal Differentiation of NSCs\
(A) Coronal sections of E14 rat brain cortex immunostained with anti-HPCA and anti-PLD1. Scale bar, 10 μm.\
(B) NSCs were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and labeled with 2 μCi/mL \[^3^H\]palmitic acid. They were pretreated with 10 μM RO320432 for 30 min and allowed to differentiate for 1 day. PLD activities were determined by measuring the formation of \[^3^H\]PBt in the presence of 1-butanol. ^∗^p \< 0.05 compared with −bFGF/*Hpca* (mean ± SD; n = 5).\
(C) Cells were transfected with control siRNA or *Hpca* siRNA for 48 hr and then incubated for 1 day after removal of bFGF. Proteins were analyzed by western blotting with anti-p-PLD1 (T147), anti-PLD1, anti-HPCA, and anti-β-ACTIN.\
(D) Cells were transfected with control siRNA, *Hpca* siRNA, or *Pld1* siRNA for 48 hr and induced to differentiate through withdrawal of bFGF. After differentiation for 3 days, cells were stained for immunocytochemical analysis of neuronal (TUJ1, green) and astrocytic (GFAP, red) markers. Scale bar, 10 μm. Graphs show the percentages of TUJ1- and GFAP-positive cells. Data are shown as mean ± SD (n = 3). ^∗^Significantly different from −bFGF/control siRNA at p *\<* 0.05 (for TUJ1). ^†^Significantly different from −bFGF/control siRNA at p *\<* 0.05 (for GFAP).\
(E) Cells were transfected with control siRNA, *Hpca* siRNA, or *Pld1* siRNA for 48 hr and induced to differentiate by withdrawal of bFGF. After differentiation for 3 days, fixed cells were immunostained with anti-TUJ1. Scale bar, 10 μm.\
(F) The numbers of spines per 10-μm dendrite were counted in randomly selected areas from at least three slides of each condition. Data are shown as mean ± SD (n = 5). ^∗^p \< 0.05 compared with the −bFGF/control siRNA. ^∗∗^p \< 0.01 compared with the −bFGF/control siRNA.](gr4){#fig4}

![Functional Analysis of STAT3(Y705) Activity in HPCA-Mediated Neuronal Differentiation\
(A) NSCs were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and induced to differentiate for 1 day. Cell lysates were analyzed by western blotting with anti-p-STAT3(Y705), anti-p-STAT3 (S727), anti-STAT3, anti-MYC, and anti-GAPDH. Data are shown as mean ± SD (n = 3). ^∗^p \< 0.05 compared with the +bFGF/vector control. ^∗∗^p \< 0.05 compared with the −bFGF/vector control.\
(B) Cells were transfected with control siRNA or *Hpca* siRNA for 48 hr and allowed to differentiate for 1 day. Proteins were analyzed by western blotting with anti-p-STAT3(Y705), anti-STAT3, anti-TUJ1, anti-GFAP, and anti-GAPDH. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(C) Diagrams of *Stat3*WT (wild-type) and *Stat3*YF (mutant). CC, coiled-coil domain; DBD, DNA-binding domain; LK, linker domain; SH2, Src homology 2; TA, transcriptional activation domain.\
(D) Vector (pBOS-FLAG), *Stat3*WT, or *Stat3*YF were transfected into NSCs for 48 hr, and the cells were induced to differentiate for 2 days. Cells were lysed and analyzed by western blotting with anti-p-STAT3(Y705), anti-STAT3, anti-TUJ1, anti-GFAP, and anti-GAPDH.\
(E and F) Cells were transfected with *Stat3*WT or *Stat3*YF for 48 hr. After differentiation for 3 days, cells were stained for neuronal (TUJ1, green) and astrocytic (GFAP, red) markers. Scale bar, 10 μm. Graphs show the percentages of TUJ1- and GFAP-positive cells. Data are shown as mean ± SD (n = 3). ^∗^Significantly different from −bFGF/*Stat3*WT at p *\<* 0.05 (for TUJ1). ^†^Significantly different from −bFGF/*Stat3*WT at p *\<* 0.05 (for GFAP).\
(G) Neurite lengths were measured in randomly selected areas from at least three slides of each condition. ^∗^p \< 0.05 compared with −bFGF/*Stat3*WT (mean ± SD; n = 3).\
(H) Cells infected with retroviruses expressing pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* were transiently transfected with *Stat3*WT or *Stat3*YF for 48 hr. The cells were induced to differentiate for 2 days. Levels of TUJ1 and GFAP were determined by western blotting. Data are shown as mean ± SD (n = 3). ^∗^p *\<* 0.05, ^∗∗^p *\<* 0.01.\
(I and J) Cells were treated as in (H) and induced to differentiate for 3 days. Cells were stained for immunocytochemical analysis of neuronal (TUJ1, green) and astrocytic (GFAP, red) markers. Scale bar, 10 μm. Graphs show the percentages of TUJ1- and GFAP-positive cells. Data are shown as mean ± SD (n = 3). ^∗^Significantly different from −bFGF/*Stat3*WT/*Hpca* at p *\<* 0.05 (for TUJ1). ^†^Significantly different from −bFGF/*Stat3*WT/*Hpca* at p *\<* 0.05 (for GFAP).\
(K) Neurite lengths were measured in randomly selected areas from at least three slides of each condition. ^∗^p \< 0.05 compared with −bFGF/*Stat3*WT/*Hpca* (mean ± SD; n = 3).](gr5){#fig5}

![Dephosphorylation of STAT3(Y705) by SHP-1 Is Related to the Neuronal Differentiation of NSCs\
(A) NSCs were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr before pretreatment with 1 μM PTPI(1) for 30 min. Cells were then allowed to differentiate for 1 day before lysis and analysis by western blotting with anti-p-STAT3(Y705), anti-STAT3, anti-TUJ1, anti-GFAP, anti-MYC, and anti-GAPDH. ^∗^p \< 0.05 compared with −bFGF/*Hpca* (mean ± SD; n = 3).\
(B) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and then treated with 1 μM PTPI(1) for 30 min before differentiation for 1 day. Fixed cells were immunostained with anti-STAT3 (red) and anti-DAPI (blue); STAT3 nuclei were counted. Arrows indicate magnified cells. Graphs show the ratio of STAT3 nuclei to total nuclei in random areas from at least three slides of each condition. ^∗^p \< 0.05 compared with −bFGF/*Hpca* (mean ± SD; n = 3).\
(C and D) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and pretreated with 1 μM PTPI(1) for 30 min. After differentiation for 3 days, cells were analyzed immunocytochemically using neuronal (TUJ1, green) and astrocytic (GFAP, red) markers. Scale bar, 50 μm. Graphs show the percentages of TUJ1- and GFAP-positive cells. Data are shown as mean ± SD (n = 3). ^∗^Significantly different from −bFGF/*Hpca* at p *\<* 0.05 (for TUJ1). ^†^Significantly different from −bFGF/*Hpca* at p *\<* 0.05 (for GFAP).\
(E) Cells were transfected with control siRNA or *Shp-1* siRNA for 48 hr and allowed to differentiate for 1 day. Proteins were analyzed by western blotting with anti-p-STAT3(Y705), anti-STAT3, anti-SHP-1, and anti-GAPDH. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(F) Cells were transfected with pMSCV-IRES-EGFP or pMSCV-IRES-EGFP-*Hpca*-*Myc* for 48 hr and induced to differentiate for 24 hr. Anti-SHP-1 immunoprecipitates from the cell lysates were analyzed by western blotting with anti-STAT3, anti-p-STAT3, anti-SHP-1, and anti-MYC.](gr6){#fig6}

![SHP-1 Is Required for Neuronal Differentiation of NSCs\
(A) NSCs were treated with 10 μM or 20 μM phosphatidic acid (PA) for 1 day in the presence of bFGF. Cell lysates were analyzed by western blotting with anti-p-SHP-1, anti-SHP-1, anti-p-STAT3(Y705), anti-STAT3, and anti-GAPDH.\
(B) Cells were transfected with control siRNA or *Pld1* siRNA for 48 hr and allowed to differentiate for 1 day. Proteins were analyzed by western blotting with anti-p-SHP1 (Y536), anti-SHP-1, anti-PLD1, and anti-GAPDH. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(C) Cells were transfected with control siRNA or *Hpca* siRNA for 48 hr and allowed to differentiate for 1 day. Cell lysates were analyzed by western blotting with anti-p-SHP1 (Y536), anti-SHP-1, anti-HPCA, and anti-GAPDH. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(D) Cells were transfected with control siRNA, *Hpca* siRNA, or *Pld1* siRNA for 48 hr and allowed to differentiate for 1 day. SHP-1 activity was measured by phosphatase activity assay (see [Experimental Procedures](#sec4){ref-type="sec"}). ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 5).\
(E and F) Cells were transfected with control siRNA or *Shp-1* siRNA for 48 hr and allowed to differentiate for 3 days. Fixed cells were immunostained with anti-TUJ1 and anti-GFAP, and TUJ1- and GFAP-positive cells were counted. Scale bar, 20 μm. Graphs show the percentages of TUJ1- and GFAP-positive cells. Data are shown as mean ± SD (n = 5). ^∗^Significantly different from −bFGF/control siRNA at p *\<* 0.05 (for TUJ1). ^†^Significantly different from −bFGF/control siRNA at p *\<* 0.05 (for GFAP).\
(G) Neurite lengths were measured in randomly selected areas from at least three slides of each condition. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(H) Cells were transfected with control siRNA or *Shp-1* siRNA for 48 hr and induced to differentiate by withdrawal of bFGF. After differentiation for 3 days, fixed cells were immunostained with anti-TUJ1. Scale bar, 10 μm. The numbers of spines per 10-μm dendrite were counted in randomly selected areas from at least three slides of each condition. ^∗^p \< 0.05 compared with the −bFGF/control siRNA (mean ± SD; n = 3).\
(I) The model suggests that HPCA plays a crucial role in neurogenesis through modulation of the PKCα/PLD1/SHP-1/STAT3 signaling pathway.](gr7){#fig7}
